The stock will trade on OCS-01 DIAMOND topline data expected in June 2026 — a binary catalyst for a potential first-in-class non-invasive DME treatment. Monitor for any pre-readout leaks or analyst days. The EPS miss is minor for a pre-revenue biotech; the cash runway and regulatory milestones are the key drivers.
Price Chart
Executive Summary
Oculis reported Q1 2026 EPS of CHF -0.49 (vs consensus $-0.41), a miss of ~2.7% on a USD-converted basis. The company highlighted strong cash runway into 2H 2029 and key upcoming catalysts: OCS-01 DME Phase 3 topline data in June 2026, Licaminlimab DED precision-medicine readout around year-end, and an FDA SPA agreement for Privosegtor in optic neuritis. The EPS miss is modest for a pre-revenue biotech, and the pipeline milestones dominate the stock narrative.
Key Financial Metrics
Key Facts
- Q1 2026 net loss CHF 28.9M ($36.8M) vs CHF 33.2M ($36.9M) in Q1 2025
- Cash, cash equivalents, and short-term investments $277.6M as of March 31, 2026
- EPS CHF -0.49 (basic and diluted) for Q1 2026
- OCS-01 DIAMOND Phase 3 DME trials completed LPLV; topline data expected June 2026
- Licaminlimab PREDICT-1 DED trial in active site recruitment; topline around year-end 2026
- Privosegtor received FDA SPA agreement for PIONEER-1 registrational trial in optic neuritis
- R&D expenses CHF 14.0M ($17.9M) vs CHF 14.8M ($16.4M) in Q1 2025
- G&A expenses CHF 7.9M ($10.1M) vs CHF 5.5M ($6.1M) in Q1 2025
Financial Impact
Net loss of CHF 28.9M ($36.8M) for Q1 2026; cash burn rate ~$12.3M/quarter; cash runway into 2H 2029
Risk Factors
- OCS-01 Phase 3 DME trials may fail to meet primary endpoints, wiping out near-term upside
- Licaminlimab precision-medicine approach may not replicate Phase 2 genotype-driven efficacy in larger Phase 3
- Privosegtor PIONEER program faces long enrollment timelines and regulatory uncertainty despite SPA
- Cash burn may accelerate if multiple trials ramp simultaneously, shortening runway from 2H 2029
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292319 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 6-K | $8.76 $8.66 | ▼ −1.14% | ▼ −2.44% | $7.83 (−10.62%) |
Aug 10, 2026 11w ago | 6-K | $12.76 $13.14 | ▲ +2.98% | ▲ +3.02% | $7.83 (−38.64%) |
Aug 10, 2026 11w ago | Press Release | $12.76 $13.14 | ▲ +2.98% | ▲ +3.02% | $7.83 (−38.64%) |
Jun 11, 2026 19w ago | Press Release | $11.00 $11.30 | ▲ +2.73% | ▲ +2.29% | $7.83 (−28.82%) |
Jun 9, 2026 20w ago | Press Release | $10.98 $11.61 | ▲ +5.74% | ▲ +3.33% | $7.83 (−28.69%) |
May 29, 2026 21w ago | Press Release | $22.71 $11.21 | ▲ +50.63% | ▲ +48.10% | $7.83 (+65.51%) |
May 11, 2026 24w ago | Press Release | $30.41 $28.07 | ▼ −7.69% | ▼ −7.77% | $7.83 (−74.25%) |
May 11, 2026 24w ago | Press Release | $30.41 $28.07 | ▼ −7.69% | ▼ −7.77% | $7.83 (−74.25%) |
May 7, 2026 24w ago | Press Release | $31.09 $31.37 | ▲ +0.90% | ▼ −0.60% | $7.83 (−74.82%) |
May 5, 2026 25w ago | Press Release | $27.75 $30.41 | ▲ +9.59% | ▲ +7.60% | $7.83 (−71.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers